Form 4: Verve Therapeutics Director Sheila Mikhail Reports Stock Option Grant

Director Sheila Mikhail reports the acquisition of stock options in Verve Therapeutics, Inc.

Summary

• Sheila Mikhail, a director of Verve Therapeutics, Inc., reported a transaction on June 26, 2024.
• Mikhail acquired stock options to purchase 136,139 shares of common stock at an exercise price of $5.02 per share.
• The options were granted under the 2021 Stock Incentive Plan as part of the director compensation program.
• The options vest upon the earlier of one year from the grant date or immediately before the first annual meeting of stockholders after the grant date, contingent on continued service as a director.
• Following the transaction, Mikhail beneficially owns 136,139 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects a standard compensation practice that aligns director interests with shareholders. There are no indications of negative news or concerns.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service as a director.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the stock option grant suggests an expectation of continued service from the director.

Industry Context

Stock option grants to directors are a common practice in the biotechnology industry to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of director compensation packages in the biotech industry.
• The vesting schedule of one year or prior to the next annual meeting is typical for director stock options.
• Comparable companies like CRISPR Therapeutics and Editas Medicine also utilize stock options as part of their director compensation.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially leading to decisions that benefit shareholders.
• The vesting schedule incentivizes the director to remain with the company, providing stability and experience.

Key Dates